Since Syk and Btk showed important regulation of both BcR and FcR signaling, specific pharmacological inhibitors for these kinases are currently undergoing preclinical and clinical trials as treatment for autoimmune diseases and hematological cancers. The gene discussed is BTK; the disease is hematopoietic and lymphoid cell neoplasm.